ReviewCNS drugs2018
An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis.
Review in CNS drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Meta-synthesis of the motherhood-related needs of women with multiple sclerosis.BMC women's health · 2024Pooled it
- Understanding the meaning of the lived experience "maternal role" in women with multiple sclerosis and planning a supportive program: a combined exploratory study protocol.Reproductive health · 2024Article
- Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy.Degenerative neurological and neuromuscular disease · 2022Review
- Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies.Frontiers in neurology · 2021Review
- Teriflunomide-exposed pregnancies in a French cohort of patients with multiple sclerosis.Neurology. Clinical practice · 2020Article
- Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure.Therapeutic advances in neurological disorders · 2020Article
- Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations.Journal of drug assessment · 2020Article
- Managing Risks with Immune Therapies in Multiple Sclerosis.Drug safety · 2019Review
- Women's Health: Contemporary Management of MS in Pregnancy and Post-Partum.Biomedicines · 2019Review
- Dynamic Balance of Microglia and Astrocytes Involved in the Remyelinating Effect of Ginkgolide B.Frontiers in cellular neuroscience · 2019Article
- Practical Evidence-Based Recommendations for Patients with Multiple Sclerosis Who Want to Have Children.Neurology and therapy · 2018Review
- Pregnancy and multiple sclerosis: Risk of unplanned pregnancy and drug exposure in utero.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The active management of multiple sclerosis (MS) has been made possible during the last two decades with the advent of disease-modifying therapies (DMTs), leading to improved clinical outcomes for many patients. Furthermore, with the realization that MS does not adversely affect pregnancy outcome and that pregnancy does not have an overall negative impact on the long-term disease course of MS, the importance of appropriate counseling and discussion of future pregnancy plans with women of childbearing age is greater than ever. Although several DMTs are licensed for the treatment of MS, none are specifically approved for use during pregnancy or breastfeeding and the use of DMTs during these periods frequently gives rise to concerns regarding potential risks to the fetus. The outcomes of studies in patients with MS treated with DMTs during pregnancy and immediately postpartum have been the focus of several recently published papers. Given the high level of interest surrounding the prescribing of DMTs for MS patients of childbearing age, and the lack of clear guidance in this respect, the current review presents an up-to-date overview of new data, including observational data on real-world outcomes, that have been published during the last 2 years, and could inform future prescribing decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.